HANSHOW/INTERGAMMA
15.5.2024 10:01:31 CEST | Business Wire | Press release
Hanshow, a global leader in digital retail solutions, has announced its exclusive partnership with Intergamma, the market leader in the Benelux DIY sector, initiating the official installation of Hanshow's Electronic Shelf Labels (ESLs) in November 2023. This collaboration aims to deliver a unique and seamless shopping experience for customers across all channels. This collaboration signals an exciting development in the retail industry as it expands Hanshow's presence in the non-food retail sector with Intergamma operating under the prominent Gamma and Karwei brands, with nearly 400 stores in the Netherlands and Belgium. As of February 2024, installation progress includes the successful completion of ESL deployments in all 128 Karwei stores, with installations for Gamma outlets actively ongoing.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240504881462/en/
Hanshow ESLs at Intergamma. (Photo: Business Wire)
Joining forces with Hanshow and utilizing the cutting-edge electronic shelf label (ESL) solution, Intergamma will further streamline in-store operations and enhance the customer journey in its stores for certain categories. As the largest DIY online platform in the Benelux region, Intergamma is committed to breaking boundaries and offering seamless shopping from online search to in-store purchases. Hanshow's ESL solution provides real-time synchronization of product information and pricing across all channels, reducing pricing discrepancies and improving the overall in-store experience.
This partnership marks a significant milestone for both companies. Through this alliance, Intergamma will leverage Hanshow's ESL technology to provide customers with an enhanced smart shopping experience for selected categories.
The key advantages of Hanshow's ESL solutions include:
- Innovation in ESL: Hanshow is at the forefront of ESL technology, offering holistic ESL solutions specifically for the DIY industry.
- Technology Leadership: Hanshow's new generation HiLPC protocol offers retailers top-tier ESL management, rapid response times, reliable service, and precise cross-channel pricing to enhance O2O capabilities.
- Industry Expertise: Leveraging extensive experience in the DIY sector, Hanshow aids Intergamma in advancing its digital transformation efforts.
Intergamma's values of fostering a sustainable future is also aligned with the introduction of Hanshow's eco-friendly operational model.
Jurre Mulder, Chief Digital & Technology Officer at Intergamma said, “We are happy to announce our partnership with renowned supplier digital store solutions Hanshow. Through this collaboration, Intergamma demonstrates its dedication to incorporating cutting-edge technology and improving the shopping experience for its devoted customers. In the next 9 months we will roll out ESL in our stores for the paint and electrical tools departments. We're excited to raise the bar for retail innovation together.”
“This collaboration with Intergamma is an important milestone in our journey to expand into the DIY retail field,” said Liangyan Li, SVP, Head of Global Sales, Hanshow. “This partnership is a great starting point, and in the future, Intergamma and Hanshow will continue to collaborate deeply, accelerating innovation and integration, and jointly promoting the digitization and sustainable development of the DIY retail industry.”
About Intergamma
Intergamma B.V. is the market leader in the do-it-yourself market in the Benelux with its retail formulas GAMMA Netherlands, GAMMA Belgium and KARWEI. With a strong store network and cross-channel strategy, Intergamma inspires and helps its customers to turn their house and garden into a comfortable and sustainable home. Learn more: www.intergamma.nl
About Hanshow
Hanshow is a global leader in developing and manufacturing electronic shelf labels and digital store solutions. The company offers customers a series of customized IoT touchpoints and digital store solutions that deliver customer-centric insights. Hanshow's solutions have provided services to a vast number of stores in over 50 countries and regions, helping them streamline operations, optimize pricing strategies, and offer consumers a more personalized experience. Learn more: www.hanshow.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240504881462/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
European Commission Approves DAYBU® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union24.8.2026 09:01:00 CEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the European Commission (EC) has granted marketing authorization for DAYBU (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older, making it the first and only treatment approved for Rett syndrome in the European Union (EU). “The approval of DAYBU marks a significant milestone for the Rett syndrome community in the EU and advances our mission to bring this innovative treatment to patients and families who have long faced a profound unmet medical need,” said Catherine Owen Adams, Acadia’s Chief Executive Officer. “For people living with Rett syndrome, a devastating rare neurodevelopmental disorder, there have been no approved treatment options in the EU. We are proud to make DAYBU available and look forward to supporting patients, caregivers, and healthcare providers gain access to treatment." The DAYBU marketing authorization in the EU is prim
ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 124.8.2026 08:36:00 CEST | Press release
Discovered by Takeda in Japan, ORZEYFUL has the Potential to Redefine Care Beyond Individual Symptom Management for Adults Living with Narcolepsy Type 1 (NT1) Landmark Phase 3 Studies Demonstrated Significant and Meaningful Improvements Across the Full Range of NT1 Symptoms Evaluated in Clinical Trials Compared to Placebo Milestone Marks Third Major Regulatory Approval Secured for ORZEYFUL Around the World Takeda (TOKYO:4502/NYSE:TAK) announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved the use of ORZEYFUL (oveporexton) for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults. ORZEYFUL is a first-in-class oral orexin receptor 2 (OX2R) agonist and the only medicine indicated in Japan to treat the disease holistically rather than individual symptoms. The discovery of this new class of medicine originated in Takeda's laboratories in Japan. Takeda is proceeding with launch preparations and expects to make ORZEYFUL available as quickly
Fasset Hits $1B Valuation as SBI Group Leads $68M Series C to Scale AI-Powered Stablecoin Neobanking24.8.2026 08:03:00 CEST | Press release
Round led by SBI Group follows $51 million Series B raise in May 2026, marking ascent as one of the fastest-growing neobanking platforms. Capital will expand Own Network and deepen AI across stablecoin settlement, tokenization, and corridor banking. Fasset now processes more than $40 billion in annualized transaction volume, serving 3 million+ wallets and more than 1,000 enterprises across 125 countries. Fasset, the AI-powered stablecoin neobanking platform, today announced it has raised $68 million in Series C funding at a $1 billion valuation. The financing was led by SBI Group and follows Fasset’s $51 million Series B earlier this year, which brought Speedinvest onto the cap table alongside a group of strategic investors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260823503947/en/ Mohammad Raafi Hossain, Co-Founder and CEO, Fasset The new capital will support the expansion of Own Network, Fasset’s regulated financial
Zanders Expands DACH Region with New Office in Vienna, Austria24.8.2026 07:11:00 CEST | Press release
Zanders, the global treasury, risk, and technology consultancy, today announced a significant expansion of its DACH region with the opening of a new office in Vienna. The move builds on Zanders' continued growth across Germany, Austria, and Switzerland, and marks another step in the firm's strategy of deepening its presence in the markets where client demand for specialized treasury, risk, and corporate finance advisory is growing fastest. DACH has been one of Zanders' priority regions for several years, with the firm steadily expanding its team and client base across Germany and Switzerland. Austria represents a natural next step in that growth: in conversations with clients in the market, Zanders has seen growing interest in treasury transformation and financing support, as companies work through interest rate volatility, refinancing needs, and a broader shift toward more digitized, centralized treasury operations. The new Vienna office allows Zanders to be closer to clients' operati
Novotech Strengthens Presence in Japan with Opening of Tokyo Office24.8.2026 01:01:00 CEST | Press release
Novotech, a leading global biotech CRO and full-service clinical research organization, has strengthened its established presence in Japan with the opening of a new office in Tokyo. The investment builds on Novotech’s existing operations and clinical trial activity in Japan and further enhances its ability to support Japanese biopharma companies as they advance programs regionally and across key international markets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260823592174/en/ Takeshi Mori, Novotech Country Head, Japan The Tokyo office will serve as a strategic hub for Novotech’s growing operations in Japan, providing enhanced local expertise and strengthening collaboration with clients, partners, research institutions, and innovation ecosystems across the region. Novotech is currently supporting ongoing studies in Japan and provides sponsors with integrated support across early-phase clinical development in Australia, F
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom